VAISHALI · NSE
Vaishali Pharma Limited
₹8.45
-1.52% (-₹0.13)
Prev. close
₹8.58
Volume
2,00,416
Delivery %
69.9%
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Hemanth Damodar Pathak
Headquarters
Mumbai
Website
vaishalipharma.comExchange
View on NSE ↗Key stats
Market cap
₹111.28 Cr
P/E ratio (TTM)
135.0
EPS (TTM)
₹0.00
Beta (1Y · daily vs NIFTY 50)
1.15
Beta (5Y · monthly vs NIFTY 50)
1.02
Shares float
6.74 Cr
EPS · quarter ended Dec 2024
₹0.98
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹53.77 Cr | ₹75.82 Cr | ₹69.66 Cr | ₹86.28 Cr | ₹99.03 Cr | ₹108.77 Cr | |
| EBITDA | ₹4.44 Cr | ₹8.64 Cr | ₹11.36 Cr | ₹3.17 Cr | ₹3.30 Cr | ₹7.95 Cr |
| ₹1.05 Cr | ₹4.02 Cr | ₹6.60 Cr | ₹71.89 L | ₹81.73 L | ₹4.03 Cr | |
| Diluted EPS | ₹0.1 | ₹0.38 | ₹0.59 | ₹0.06 | ₹0.31 | ₹0.31 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹78.91 Cr | ₹79.96 Cr | ₹109.84 Cr | ₹123.39 Cr | |
| — | — | ₹14.74 Cr | ₹13.49 Cr | ₹12.32 Cr | ₹18.89 Cr | |
| Stockholders' equity | — | — | ₹40.53 Cr | ₹42.84 Cr | ₹64.92 Cr | ₹69.12 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2.01 Cr | ₹1.32 Cr | ₹1.08 Cr | ₹80.67 L | ₹-18.04 Cr | ₹43.57 L | |
| Investing cash flow | ₹-11.03 L | ₹-84.68 L | ₹28.21 L | ₹1.20 Cr | ₹-18.81 L | ₹-5.46 Cr |
| ₹-1.81 Cr | ₹41.74 L | ₹-1.73 Cr | ₹-1.42 Cr | ₹18.49 Cr | ₹4.61 Cr | |
| Capital expenditure | ₹-12.60 L | ₹-86.48 L | ₹-29.72 L | ₹-11.10 L | ₹-30.46 L | ₹-45.90 L |
| End cash position | ₹46.60 L | — | ₹98.47 L | ₹1.58 Cr | ₹1.84 Cr | ₹1.43 Cr |
End cash position has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22 | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23–Jun 23(2Q) | Sep 23–Dec 23(2Q) | Mar 24 | May 24 | May 24 | Jun 24 | Jul 24 | Sep 24–Sep 25(5Q) | Dec 25–Jun 26(4Q) | Jul 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 56.31% | 26.74% | 26.74% | 26.74% | 26.74% | 26.62% | 26.32% | 25.77% | 24.87% | 26.32% | 31.61% | 26.32% | 31.61% | 30.54% |
| Public | 43.69% | 73.25% | 73.26% | 73.24% | 73.26% | 73.38% | 73.68% | 74.23% | 75.13% | 73.68% | 68.39% | 73.68% | 68.39% | 69.46% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Vaishali Pharma Limited | ₹110.24 Cr | ₹8.45 | 135.0 | 1.60 | 5.8% | 0.27 | +7.0% | -29.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.